Baricitinib: Doctors Are Skeptical of This Covid-19 Drug From Eli Lilly
In mid-November, an arthritis drug with a tricky name hit a pandemic milestone — then slipped back into relative obscurity. The drug, baricitinib, was granted an emergency authorization by the Food and Drug Administration to treat a subset of hospitalized Covid-19 patients in combination with another medication, the antiviral remdesivir. It is one of only…